A dose finding study of carboplatin and gemcitabine in advanced non-small cell lung cancer

A. Tognoni, F. Pensa, F. Vaira, A. Vigani, P. Canessa, G. Sinaccio, P. Pronzato

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The excellent activity of the cisplatin-gemcitabine combination and favorable toxicological profile of carboplatin are the basis of carboplatin-gemcitabine combination therapy for non-small cell lung cancer. We carried out a dose-finding study with the aim of establishing the maximum tolerated dose (MTD) of carboplatin on day 1 in combination with gemcitabine at the dose of 1000 mg/m2 on days 1 and 8 in a 21-day cycle. The starting dose level for carboplatin was the area under the concentration time curve (AUC) 4 mg/ml/min. 18 patients were treated and a dose limiting toxicity was observed in 2 cases at the level of AUC 6 mg/ml/min. AUC 5 mg/ml/min was considered as the MTD for carboplatin in our regimen. Notably, 7 objective responses were observed.

Original languageEnglish
Pages (from-to)296-300
Number of pages5
JournalJournal of Chemotherapy
Volume14
Issue number3
Publication statusPublished - 2002

Fingerprint

gemcitabine
Carboplatin
Non-Small Cell Lung Carcinoma
Area Under Curve
Maximum Tolerated Dose
Toxicology
Cisplatin

Keywords

  • Carboplatin
  • Gemcitabine
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)

Cite this

Tognoni, A., Pensa, F., Vaira, F., Vigani, A., Canessa, P., Sinaccio, G., & Pronzato, P. (2002). A dose finding study of carboplatin and gemcitabine in advanced non-small cell lung cancer. Journal of Chemotherapy, 14(3), 296-300.

A dose finding study of carboplatin and gemcitabine in advanced non-small cell lung cancer. / Tognoni, A.; Pensa, F.; Vaira, F.; Vigani, A.; Canessa, P.; Sinaccio, G.; Pronzato, P.

In: Journal of Chemotherapy, Vol. 14, No. 3, 2002, p. 296-300.

Research output: Contribution to journalArticle

Tognoni, A, Pensa, F, Vaira, F, Vigani, A, Canessa, P, Sinaccio, G & Pronzato, P 2002, 'A dose finding study of carboplatin and gemcitabine in advanced non-small cell lung cancer', Journal of Chemotherapy, vol. 14, no. 3, pp. 296-300.
Tognoni A, Pensa F, Vaira F, Vigani A, Canessa P, Sinaccio G et al. A dose finding study of carboplatin and gemcitabine in advanced non-small cell lung cancer. Journal of Chemotherapy. 2002;14(3):296-300.
Tognoni, A. ; Pensa, F. ; Vaira, F. ; Vigani, A. ; Canessa, P. ; Sinaccio, G. ; Pronzato, P. / A dose finding study of carboplatin and gemcitabine in advanced non-small cell lung cancer. In: Journal of Chemotherapy. 2002 ; Vol. 14, No. 3. pp. 296-300.
@article{d7f4c1485d9d4ccaa7a05b8d08e998d3,
title = "A dose finding study of carboplatin and gemcitabine in advanced non-small cell lung cancer",
abstract = "The excellent activity of the cisplatin-gemcitabine combination and favorable toxicological profile of carboplatin are the basis of carboplatin-gemcitabine combination therapy for non-small cell lung cancer. We carried out a dose-finding study with the aim of establishing the maximum tolerated dose (MTD) of carboplatin on day 1 in combination with gemcitabine at the dose of 1000 mg/m2 on days 1 and 8 in a 21-day cycle. The starting dose level for carboplatin was the area under the concentration time curve (AUC) 4 mg/ml/min. 18 patients were treated and a dose limiting toxicity was observed in 2 cases at the level of AUC 6 mg/ml/min. AUC 5 mg/ml/min was considered as the MTD for carboplatin in our regimen. Notably, 7 objective responses were observed.",
keywords = "Carboplatin, Gemcitabine, Non-small cell lung cancer",
author = "A. Tognoni and F. Pensa and F. Vaira and A. Vigani and P. Canessa and G. Sinaccio and P. Pronzato",
year = "2002",
language = "English",
volume = "14",
pages = "296--300",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "3",

}

TY - JOUR

T1 - A dose finding study of carboplatin and gemcitabine in advanced non-small cell lung cancer

AU - Tognoni, A.

AU - Pensa, F.

AU - Vaira, F.

AU - Vigani, A.

AU - Canessa, P.

AU - Sinaccio, G.

AU - Pronzato, P.

PY - 2002

Y1 - 2002

N2 - The excellent activity of the cisplatin-gemcitabine combination and favorable toxicological profile of carboplatin are the basis of carboplatin-gemcitabine combination therapy for non-small cell lung cancer. We carried out a dose-finding study with the aim of establishing the maximum tolerated dose (MTD) of carboplatin on day 1 in combination with gemcitabine at the dose of 1000 mg/m2 on days 1 and 8 in a 21-day cycle. The starting dose level for carboplatin was the area under the concentration time curve (AUC) 4 mg/ml/min. 18 patients were treated and a dose limiting toxicity was observed in 2 cases at the level of AUC 6 mg/ml/min. AUC 5 mg/ml/min was considered as the MTD for carboplatin in our regimen. Notably, 7 objective responses were observed.

AB - The excellent activity of the cisplatin-gemcitabine combination and favorable toxicological profile of carboplatin are the basis of carboplatin-gemcitabine combination therapy for non-small cell lung cancer. We carried out a dose-finding study with the aim of establishing the maximum tolerated dose (MTD) of carboplatin on day 1 in combination with gemcitabine at the dose of 1000 mg/m2 on days 1 and 8 in a 21-day cycle. The starting dose level for carboplatin was the area under the concentration time curve (AUC) 4 mg/ml/min. 18 patients were treated and a dose limiting toxicity was observed in 2 cases at the level of AUC 6 mg/ml/min. AUC 5 mg/ml/min was considered as the MTD for carboplatin in our regimen. Notably, 7 objective responses were observed.

KW - Carboplatin

KW - Gemcitabine

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0035986446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035986446&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 296

EP - 300

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 3

ER -